Alnylam Pharmaceuticals
NEWS
Pharma and biotech companies across the globe continued to expand and reshape their leadership teams with new hires this past week. BioSpace collected several announced leadership appointments, which includes new chief executive officers, new members to boards of directors and more.
Alnylam Pharmceuticals reported preclinical results that supports advancement of its RNA interference (RNAi) therapeutics for central nervous system disorders into the clinic.
The difference between the salaries paid to top executives and the median income earned by rank and file employees has been a sore subject for many years and has served as a wedge political issue in recent elections.
Fueled by positive Phase I and Phase I/II results from an open-label extension (OLE) study of RNAi therapeutic givosiran, as well as an ongoing Phase III trial, Cambridge, Mass.-based Alnylam said it is eying a possible New Drug Application by the end of the year.
Alexandria Real Estate Equities, an urban office real estate investment company specializing in the life sciences, is expanding its Alexandria LaunchLabs into the East Cambridge, Massachusetts area.
Biotech investor Vivek Ramaswamy has launched another company. This time his company, dubbed Genevant, will focus on the development of RNA-based therapies and is the combined product of Roivant Sciences and Arbutus Biopharma Corporation.
Pfizer could be eying the green light for a first-ever regulatory approved treatment for transthyretin cardiomyopathy (TTR) following positive topline results from a late-stage study.
Regeneron Pharmaceuticals and Alnylam Pharmaceuticals signed a collaboration deal to identify RNAi therapies for nonalcoholic steatohepatitis (NASH) and other possibly related liver diseases.
The stock market has been rocky recently, but overall the biotech market appears to have been comparatively stable.
JOBS
IN THE PRESS